The clinic nurse is obtaining information from a client who presents for her annual wellness exam.
Which of the following statements should be used when taking a sexual health history?

Choice A rationale

Enoxaparin (a low-molecular-weight heparin) and warfarin (a vitamin K antagonist) are anticoagulants that prevent the formation of new fibrin clots or the enlargement of existing ones, but they do not dissolve established clots; that is the function of thrombolytic agents like tissue plasminogen activator. Administering both aims for adequate anticoagulation until warfarin is fully effective. The correct response emphasizes discontinuing enoxaparin when warfarin is therapeutic.

Choice B rationale

Warfarin, an oral anticoagulant, inhibits vitamin K-dependent clotting factors (II, VII, IX, X), requiring several days to reach a therapeutic effect, which is monitored by the International Normalized Ratio (INR) (therapeutic range typically 2.0–3.0). Enoxaparin, an injectable anticoagulant with immediate onset, is continued concurrently to maintain protection until the INR is therapeutic and adequate anticoagulation is achieved via warfarin alone, a process called bridging.

Choice C rationale

Enoxaparin and warfarin have distinct mechanisms of action and do not enhance each other's effects synergistically; rather, they inhibit different points in the coagulation cascade. Enoxaparin mainly inhibits Factor Xa, while warfarin inhibits Vitamin K-dependent clotting factor synthesis. They are used together to provide immediate anticoagulation (enoxaparin) while awaiting warfarin's delayed onset.

Choice D rationale

While patient education is crucial, responding by deferring the client's question is not therapeutic and does not address the client's need for understanding their therapy. The nurse should explain the rationale for concurrent therapy (bridging) and the planned discontinuation of the injectable drug once the oral medication is within its therapeutic range.

Choice A rationale

Aspirin (acetylsalicylic acid) at a low daily dose of 81 mg is typically used for its antiplatelet effects (irreversible inhibition of COX-1 in platelets) to prevent cardiovascular events. This dose has minimal analgesic or anti-inflammatory effects. Therefore, monitoring a pain rating of 6 or more is not a primary concern for this specific prophylactic indication.

Choice B rationale

Encouraging increased intake of green leafy vegetables, which are rich in Vitamin K, is relevant for clients on warfarin (Coumadin), as Vitamin K can counteract its effect. Aspirin, however, works on platelet aggregation and is not affected by dietary Vitamin K levels. This advice is irrelevant to the pharmacodynamics of aspirin.

Choice C rationale

Aspirin is a non-steroidal anti-inflammatory drug (NSAID) that can cause gastrointestinal irritation and bleeding, a side effect that is dose-dependent but still possible with low-dose therapy. Black, tarry stools (melena) are an indication of upper gastrointestinal bleeding due to the degradation of hemoglobin to hematin. The nurse must monitor for this serious adverse effect.

Choice D rationale

Aspirin, especially at higher doses, can impair renal function by inhibiting prostaglandin synthesis, which is essential for maintaining renal blood flow. This effect typically leads to an increase (not a sudden drop) in blood urea nitrogen (BUN) (normal range 8-20 mg/dL) and creatinine (normal range 0.6-1.2 mg/dL) levels due to decreased glomerular filtration.